|drug3669||allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC) Wiki||1.00|
|drug3153||Standard of care therapy Wiki||1.00|
|drug1684||Intravenous saline injection (Placebo) Wiki||1.00|
There is one clinical trial.
Randomized controlled interventional trial (Clinical Trial) phase 3 to assess the safety and efficacy of favipiravir versus the standard care therapy in the treatment of patients with COVID-19.
Description: Two successive negative COVID-19 PCR analysis tests 48-72 hours apartMeasure: Viral clearance Time: 14 days
Description: Normal body temperature for 48 hoursMeasure: Clinical improvement Time: 14 days
Description: Improvement of radiological abnormalities at day 14Measure: Radiological Improvement Time: 14 days
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports